Genesis Therapeutics Secures $52M Series A to Further Accelerate AI Innovation and to Launch Drug Discovery & Development Pipeline Led by Rock Springs Capital with participation by funds and accounts advised by T. Rowe Price Associates, Inc., Andreessen Horowitz, and other major investors BURLINGAME, Calif., December 2, 2020-- Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, has completed its $52M Series A financing round. Rock Springs Capital led the round.